Mitotic index is an independent predictor of recurrence-free survival in meningioma

Brain Pathology

Volumn 25, Issue 3, 2015, Pages 266-275

  Olar, Adriana ^a   Wani, Khalida M ^a   Sulman, Erik P ^a   Mansouri, Alireza ^a   Zadeh, Gelareh ^a   Wilson, Charmaine D ^a   Demonte, Franco ^b   Fuller, Gregory N ^a   Aldape, Kenneth D ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Meningioma; Mitotic index; pHH3; Recurrence free survival

Indexed keywords

HISTONE H3; HISTONE; KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; CANCER CELL; CHILD; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONFERENCE PAPER; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MITOSIS INDEX; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; COMPUTED TOMOGRAPHY SCANNER; DISEASE FREE SURVIVAL; MENINGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORYLATION; PREDICTIVE VALUE; PROCEDURES; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HISTONES; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; YOUNG ADULT;

EID: 84928332500     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12174     Document Type: Conference Paper

References (49)

1. Abry E, Thomassen IO, Salvesen OO, Torp SH, (2010) The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Pract 206: 810-815.
2. Adlakha RC, Rao PN, (1986) Molecular mechanisms of the chromosome condensation and decondensation cycle in mammalian cells. Bioessays 5: 100-105.
3. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, et al (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64: 56-60.
4. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, Vandertop WP, et al (2012) Impaired survival and long-term neurological problems in benign meningioma. Neuro-Oncol 14: 658-666.
5. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K, (2001) Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 32: 970-975.
6. Breiman L, Friedman J, Olshen RA, Stone JC, (1983) Classification and Regression Trees, 1st edn. Chapman and Hall/CRC: Boca Raton, FL.
7. Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Glass LF, (2010) Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 32: 650-654.
8. Domingues PH, Sousa P, Otero A, Goncalves JM, Ruiz L, de Oliveira C, et al (2014) Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro-Oncol 16: 735-747.
9. Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y, Shigemori M, (2009) Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 26: 51-57.
10. Glatz K, Hartmann C, Antic M, Kutzner H, (2010) Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Am J Dermatopathol 32: 643-649.
11. Habberstad AH, Gulati S, Torp SH, (2011) Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol 6: 43.
12. Hardesty DA, Wolf AB, Brachman DG, McBride HL, Youssef E, Nakaji P, et al (2013) The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg 119: 475-481.
13. Heald JB, Carroll TA, Mair RJ, (2014) Simpson grade: an opportunity to reassess the need for complete resection of meningiomas. Acta Neurochir (Wien) 156: 383-388.
14. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106: 348-360.
15. Hendzel MJ, Nishioka WK, Raymond Y, Allis CD, Bazett-Jones DP, Th'ng JP, (1998) Chromatin condensation is not associated with apoptosis. J Biol Chem 273: 24470-24478.
16. Ho DM, Hsu CY, Ting LT, Chiang H, (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94: 1538-1547.
17. Idriss MH, Kazlouskaya V, Malhotra S, Andres C, Elston DM, (2013) Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm). J Cutan Pathol 40: 557-563.
18. Ildan F, Erman T, Gocer AI, Tuna M, Bagdatoglu H, Cetinalp E, Burgut R, (2007) Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base 17: 157-171.
19. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T, (2006) Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 29: 293-296, discussion 6-7.
20. Kim YJ, Ketter R, Steudel WI, Feiden W, (2007) Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 128: 118-125.
21. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (2007) WHO Classification of Tumors of the Central Nervous System, 4th edn. IARC: Lyon, France.
22. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, et al (1996) Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91: 504-510.
23. Moon HS, Jung S, Jang WY, Jung TY, Moon KS, Kim IY, (2012) Intracranial meningiomas, WHO grade II: prognostic implications of clinicopathologic features. J Korean Neurosurg Soc 52: 14-20.
24. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M, (2001) Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am J Surg Pathol 25: 472-478.
25. NCCN (2014) Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2.
26. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncol 15 (Suppl. 2): ii1-ii56.
27. Oya S, Kawai K, Nakatomi H, Saito N, (2012) Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas. J Neurosurg 117: 121-128.
28. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM, (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21: 1455-1465.
29. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM, (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82: 2262-2269.
30. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC, (1999) "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85: 2046-2056.
31. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105: 1897-1906.
32. Posnett D, Devanbu PT, Filkov V, (2012) MIC check: a correlation tactic for ESE data. IEEE. 22-31.
33. R Core Team (2014) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. Available at: http://www.R-project.org/ (accessed March, 2014).
34. Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, Turnbaugh PJ, et al (2011) Detecting novel associations in large data sets. Science 334: 1518-1524.
35. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN, (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28: 1532-1536.
36. Ruiz J, Martinez A, Hernandez S, Zimman H, Ferrer M, Fernandez C, et al (2010) Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol 25: 341-349.
37. Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, et al (2012) pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol 34: 266-269.
38. Shibata K, Ajiro K, (1993) Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem 268: 18431-18434.
39. Shibata K, Inagaki M, Ajiro K, (1990) Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem 192: 87-93.
40. Simpson D, (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20: 22-39.
41. Solomides CC, Birbe RC, Nicolaou N, Bagley D, Bibbo M, (2012) Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks? Acta Cytol 56: 285-288.
42. Speed T, (2011) Mathematics. A correlation for the 21st century. Science 334: 1502-1503.
43. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG, (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73: 936-942.
44. Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach LM, Kerfoot CA, (2012) Level of phosphohistone H3 among various types of human cancers. BMJ Open 2: 1-6.
45. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K, (2006) Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 30: 83-89.
46. Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, et al (2013) Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol 26: 1153-1160.
47. Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA, (2011) Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 136: 252-259.
48. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 7: e37379.
49. Veras E, Malpica A, Deavers MT, Silva EG, (2009) Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 28: 316-321.